activated lymphocytes. Some of these 7 transmembrane-spanning, G-protein-coupled receptors are also necessary for HIV entry (1) (2) (3) (4) (5) . Macrophagetropic (M-tropic) (R5) HIV-1 strains predominantly use CCR5 as a coreceptor for infection, whereas T cell-tropic (T-tropic) (X4) HIV-1 strains enter via CXCR4, the unique but widely expressed receptor for stromal cell-derived factor-1 (SDF-1) (3, 5) .
MIP-1α has originally been isolated from murine macrophages as an inflammatory mediator and inhibitor of hematopoietic stem cell proliferation (6, 7) . Human MIP-1α, the first human CC chemokine for which the cDNA sequence has been reported, is encoded by 2 highly related nonallelic genes (8) (9) (10) (11) , designated LD78α and LD78β, that are expressed in lymphocytes and monocytes. So far, only recombinant LD78α has been investigated in detail; it was found to chemoattract monocytes, lymphocytes, natural killer cells, dendritic cells, eosinophils, and basophils (3) (4) (5) . The 2 MIP-1α isoforms differ only in 3 amino acids: the penultimate NH 2 -terminal residue and amino acids 39 and 47. Many studies have indicated the importance of the NH 2 -terminal regions of both CXC and CC chemokines for their biological activity (2, (12) (13) (14) (15) . Because modification or deletion of a single residue may result in altered chemokine receptor usage, and hence target cell specificity, we have investigated both isoforms of MIP-1α in more detail. We believe that this study describes for the first time the isolation of natural LD78β. We show that this MIP-1α isoform is a potent lymphocyte and monocyte chemoattractant that preferentially signals through CCR5 and is the most potent chemokine in inhibiting infection of peripheral blood mononuclear cells (PBMCs) by R5 HIV-1. (17) were cultured in DMEM supplemented with 10% FCS and puromycin (1 µg/mL; Sigma Chemical Co., St.
Methods
LD78α and LD78β are 2 highly related nonallelic genes that code for different isoforms of the human CC chemokine macrophage inflammatory protein-1α (MIP-1α). Two molecular forms of natural LD78β (7.778 and 7.793 kDa) were identified from conditioned media of stimulated peripheral blood mononuclear cells. Although LD78α and LD78β only differ in 3 amino acids, both LD78β variants were 100-fold more potent chemoattractants for mouse lymphocytes than was LD78α. On the contrary, LD78β was only 2-fold more efficient than LD78α in chemoattracting human lymphocytes and monocytes. Using CC chemokine receptor-transfected cells, both molecular forms of LD78β proved to be much more potent than LD78α in inducing an intracellular calcium rise through CCR5. Compared with LD78α and RANTES, this preferential binding of LD78β to CCR5 resulted in a 10-to 50-fold higher potency in inhibiting infection of peripheral blood mononuclear cells by CCR5-using (R5) HIV-1 strains. To date, LD78β is the most potent chemokine for inhibiting HIV-1 infection, and can be considered as a potentially important drug candidate for the treatment of infection with R5 HIV-1 strains.
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Louis, Missouri, USA). PBMCs were isolated by hydroxyethyl starch sedimentation and Ficoll-sodium metrizoate centrifugation (13) . Lymphocytes and monocytes were further separated on magnetic beads, coated with anti-CD3 (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany).
RANTES and the human recombinant MIP-1α isoform LD78α were purchased from PeproTech Inc. (Rocky Hill, New Jersey, USA) and BioSource Europe (Fleurus, Belgium). The 7.793-kDa LD78β was synthesized by FMOC solidphase peptide synthesis (18) . 125 I-RANTES was purchased from Amersham Pharmacia Biotech (Roosendaal, the Netherlands).
Production, purification. and identification of natural MIP-1α isoforms. PBMCs (54 × 10 9 cells) from 132 blood donations were incubated for 48 hours in EMEM (GIBCO BRL) plus 2% FCS supplemented with 10 µg/mL Con A (Calbiochem-Novabiochem Corp., San Diego, California, USA) and 2 µg/mL LPS (from Escherichia coli 0111:B4; Difco Laboratories, Detroit, Michigan, USA). Natural MIP-1α isoforms were isolated through a 4-step concentration and purification procedure (13) comprising adsorption to silicic acid, heparin-Sepharose chromatography, cation exchange chromatography, and reverse-phase HPLC (RP-HPLC). Fractions derived from RP-HPLC were checked for purity by SDS-PAGE under reducing conditions (13) . MIP-1α proteins were viewed by silver staining, and the following molecular weight markers were used: carbonic anhydrase (M r = 31 kDa), soybean trypsin inhibitor (M r = 21 kDa), lysozyme (M r = 14 kDa), and aprotinin (M r = 6.5 kDa). NH 2 -terminal amino acid sequences of pure MIP-1α forms were obtained by Edman degradation, using a pulsed liquid-phase 477A/120A protein sequencer (PerkinElmer Applied Biosystems, Foster City, California, USA). To distinguish LD78β forms, purified proteins were subjected to electrospray mass spectrometry (LCQ-Iontrap; Finnigan, San Jose, California, USA).
Chemokine assays. MIP-1α immunoreactivity was measured by a specific sandwich ELISA (BioSource Europe), kindly supplied by J.-M. Jaspar. The cellular expression of chemokine receptors was examined by flow cytometric analysis, using mAb's against CCR1 (R&D Systems Inc., Minneapolis, Minnesota, USA) and CCR5 (PharMingen, San Diego, California, USA). Competition for 125 I-RANTES binding was analyzed on CCR1-and CCR5-transfected HOS cells as previously described (19) . MIP-1α isoforms were tested for their chemotactic potency on freshly isolated monocytes (2 × 10 6 cells/mL), CD3 + lymphocytes (10 × 10 6 cells/mL), monocytic THP-1 cells (0.5 × 10 6 cells/mL), and lymphocytic ESb/MP cells (2 × 10 6 cells/mL), in the Boyden microchamber (Neuro Probe Inc., Cabin John, Maryland, USA) (13, 16) . The chemotactic index (number of chemoattracted cells divided by the number of randomly migrated cells) was used as a parameter for potency. Intracellular calcium concentrations ([Ca 2+ ] i ) were measured by fluorescence spectrophotometry and calculated according to the Grynkiewicz equation (13) .
Inhibition of HIV-1 infection. The R5 HIV-1 strain BaL was obtained through the Medical Research Council AIDS Reagent Project (National Institute for Biological Standards and Control, Herts, United Kingdom). Purified PBMCs, stimulated with PHA (1 µg/mL for 3 days), were infected with virus in the presence of 25 U/mL of IL-2 and various concentrations of LD78α, LD78β, or RANTES (12) . Cell supernatant was collected at day 10, and HIV-1 core antigen in the supernatant was analyzed by a p24 antigen ELISA kit (NEN Life Science Products Inc., Boston, Massachusetts, USA).
Results
Identification of natural LD78β isoforms from stimulated mononuclear cells.
Conditioned medium from PBMCs stimulated with mitogen and endotoxin was analyzed for its MIP-1α content using a specific ELISA and the sensitive lymphocyte (ESb/MP cells) chemotactic assay. With an established procedure for chemokine isolation (13) , MIP-1α isoforms were fractionated and finally purified to homogeneity by RP-HPLC (Figure 1a) . MIP-1α immunoreactivity and chemotactic activity corresponded to a minor peak containing a single protein of 8 kDa and to a major peak of 7-8 kDa MIP-1α (Figure 1b) (Figure 2) . Moreover, at optimal concentrations, 2.5 times more ESb/MP cells migrated in response to LD78β compared with LD78α. In contrast, LD78α and LD78β were equally potent as chemoattractants for monocytic THP-1 cells, with a minimal effective concentration of 1 ng/mL. Similarly, LD78α was equipotent to LD78β in inducing calcium mobilization in THP-1 cells (data not shown). Additional experiments on freshly isolated monocytes and CD3 + lymphocytes indicated that LD78β was only 2-fold more potent than LD78α. Taken together, these findings indicated that, despite minor structural differences between the MIP-1α isoforms, LD78α and LD78β show diverging chemotactic potencies. Because monocyte and lymphocyte populations were found to express both CCR1 and CCR5, as determined by flow cytometric analysis (data not shown), the effect of the ligands LD78α and LD78β on these chemokine receptors was further investigated.
Inverse chemokine receptor recognition by LD78α and LD78β. First, we studied whether the 7.793-kDa LD78β differed from LD78α in order to compete with 125 I-labeled RANTES for receptor binding on CCR1-and CCR5-transfected HOS cells. LD78α and LD78β displaced 125 I-RANTES from CCR1 equally well, whereas on CCR5 transfectants, LD78β was superior to LD78α (data not shown).
LD78α strongly induced calcium mobilization in CCR1 transfectants (minimal effective concentration: 3 ng/mL), whereas LD78β (7.778 and 7.793 kDa) yielded a significant effect only from 10 ng/mL onward (Figure 3) . In contrast, in CCR5 transfectants, both LD78β forms induced calcium mobilization more efficiently than RANTES and LD78α (minimal effective concentration: 3 vs. 30 and 100 ng/mL, respectively), indicating an inverse receptor preference of these MIP-1α isoforms. A small difference between both LD78β forms, in favor of the 7.778-kDa variant, was observed on CCR5 transfectants. The maximal calcium response of LD78β on CCR5 was 3-fold higher than that of LD78α and RANTES. The 30-fold higher potency of LD78β, compared with LD78α, to signal through CCR5 suggested that LD78α and LD78β might differ in their ability to block CCR5 binding by M- tropic HIV-1 strains.
Higher potency of LD78β, compared with LD78α and RANTES, in inhibiting HIV-1 infection. LD78α and LD78β were compared for their capacity to prevent HIV-1 infection of PBMCs by the Mtropic BaL strain, which uses CCR5 as a coreceptor to enter the cells. As could be predicted by the receptor recognition patterns, LD78β (7.778 and 7.793 kDa) was found to be a more potent inhibitor of HIV-1 infection than LD78α and RANTES, both known to block M-tropic strains via CCR5 (Figure 4) . The 7.778-kDa LD78β form seemed to be more effective compared with the 7.793-kDa LD78β form. On average, the IC 50 values were about 1, 5, 60 and 100 ng/mL for 7.778-kDa LD78β, 7.793-kDa LD78β, RANTES, and LD78α, respectively. This more than 20-fold difference in antiviral potency between LD78α and LD78β reflects their differences in CCR5 signaling capacity.
Discussion
The human macrophage inflammatory proteins MIP-1α and MIP-1β, mainly produced by mononuclear leukocytes (2), display different chemotactic activities despite their high structural relationship (70% identical amino acids). The diverging effects of MIP-1α and MIP-1β on leukocytes can be explained by the fact that MIP-1α signals through CCR1 and CCR5, whereas MIP-1β does not bind CCR1 (1) (2) (3) (4) (5) . The anti-HIV-1 activities of MIP-1α and MIP-1β are both mediated through CCR5 binding (17, (20) (21) (22) (23) . For MIP-1α, 2 isoforms (LD78α and LD78β) have been reported, but so far only the biological activities and receptor binding properties of LD78α have been investigated in detail (8) (9) (10) (11) (20) (21) (22) (23) . The primary structure of LD78α and LD78β differs in 3 amino acids, including 1 residue in the NH 2 -terminal region, which may be important for receptor binding, as shown for other chemokines (2, (12) (13) (14) (15) .
This study describes the isolation and biological characterization of natural LD78β from stimulated leukocytes. Two variants of natural NH 2 -terminally intact LD78β, characterized by different molecular masses, were recovered. The 7.794-kDa LD78β variant, with a molecular mass corresponding to the theoretical mass (7.793 kDa), was impure and was synthesized to be compared with the 7.778-kDa variant, lacking 0.016 kDa. Compared with LD78α, both LD78β variants were found to be 100-fold more potent in chemoattracting ESb/MP lymphocytic cells, whereas no difference was observed on THP-1 monocytic cells. On freshly isolated blood monocytes and CD3 + lymphocytes, both LD78β variants seemed to be only 2-fold better chemoattractants than LD78α. By means of the calcium mobilization assay, using CCR transfectants, it was further shown that LD78α signals predominantly via CCR1. In contrast, LD78β activates CCR5 more efficiently than LD78α or RANTES. This probably explains the differences in chemotactic potencies observed between LD78α and LD78β. Finally, the preference of both LD78β isoforms for CCR5 was biologically confirmed on PBMCs by their 10-to 50-fold higher antiviral activity against M-tropic HIV-1 strains compared with RANTES and LD78α. The reported rank order amongst CC chemokines for antiviral potency is RANTES>MIP-1β>MIP-1α/LD78α (24) . Our findings that RANTES and LD78α have an IC 50 of about 60 and 100 ng/mL, respectively, are in agreement with these published data (24) . The fact that the IC 50 for SDF-1, when evaluated against different T-tropic HIV isolates, was as high as 200-3,500 ng/mL demonstrates that LD78β (IC 50 : 1-5 ng/mL) is the most potent chemokine reported to date for inhibiting HIV-1 infection. This superior anti-HIV-1 activity of LD78β needs to be reconsidered in the light of the isolation of MIP-1α, MIP-1β, and RANTES from cultured T cells as suppressors of HIV-1 infection (20) . Although not investigated in the latter study (20) , it can be deduced from our data that the antiviral effect corresponding to MIP-1α was likely due to LD78β. A reported overproduction of the CC chemokines MIP-1α, MIP-1β, and RANTES correlated with the protection against HIV-1 infection (25) (26) . Moreover, MIP-1α appeared faster and reached higher concentrations than MIP-1β or RANTES (25) (26) . These clinical data demonstrating natural resistance to HIV-1 infection, which was not linked to a mutation deletion in the CCR5 gene, are in agreement with the higher antiviral potency of the LD78β isoforms of MIP-1α observed in our study.
The fact that we could only recover intact LD78β from stimulated mononuclear cells points to a higher resistance of LD78β to posttranslational processing by proteolytic cleavage. Nevertheless, both truncated LD78α and LD78β, missing 4 NH 2 -terminal residues, were purified from leukocyteconditioned media. In a previous study,
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Figure 4
Inhibition of R5 HIV-1 infection by LD78β. (12, (14) (15) . Although posttranslational processing of MDC and RANTES seemed to improve their antiviral capacity, both truncated MDC and RANTES remained far inferior for blocking HIV-1 replication in PBMCs when compared with LD78β (12, 15) . In view of the importance of the NH 2 -terminal region of chemokines for receptor recognition, the substitution of the penultimate serine residue in LD78α by a proline in LD78β is probably responsible for the receptor switch from CCR1 to CCR5. In addition to HIV-1 infection, the role of MIP-1α has been studied in other human pathologies, including airway inflammation and autoimmune disease (1). Using immunotests recognizing both LD78α and LD78β, elevated MIP-1α levels have been detected in bronchoalveolar lavage fluids of asthma patients. Similarly, MIP-1α immunoreactivity is significantly present in the synovial fluid during rheumatoid arthritis. The involvement of MIP-1α in eosinophilic and mononuclear leukocyte infiltration has been confirmed in animal models by blocking antibodies (1) . Because no MIP-1α isoforms have been described in the mouse, and human LD78α and LD78β are immunologically indistinguishable, the individual roles of LD78α and LD78β in these human diseases remain, at present, unknown.
